Pregled bibliografske jedinice broj: 933973
Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer’s disease and vascular dementia
Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer’s disease and vascular dementia // CNS Neuroscience & Therapeutics, 24 (2018), 734-740 doi:10.1111/cns.12814 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 933973 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Evaluation of cerebrospinal fluid phosphorylated
tau231 as a biomarker in the differential
diagnosis of Alzheimer’s disease and vascular
dementia
Autori
Kiđemet-Piskač, Spomenka ; Babić Leko, Mirjana ; Blažeković, Antonela ; Horvat Langer, Lea ; Klepac, Nataša ; Sonicki, Zdenko ; Kolenc, Danijela ; Hof, Patrick R. ; Boban, Marina ; Mimica, Ninoslav ; Borovečki, Fran ; Šimić, Goran
Izvornik
CNS Neuroscience & Therapeutics (1755-5930) 24
(2018);
734-740
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Alzheimer's disease ; biomarkers ; cerebrospinal fluid ; tau proteins ; vascular dementia
Sažetak
Background: The diagnosis of either Alzheimer's disease (AD) or vascular dementia (VaD) is still largely based on clinical guidelines and exclusion of other diseases that may lead to dementia. Aims: In this study, we assessed whether the use of sensitive and specific biomarkers such as phosphorylated tau proteins could contribute to an earlier and more accurate diagnosis of AD and VaD, as well as to their differentiation. Material and methods: A total of 198 patients, of which 152 had AD, 28 VaD, and 18 were healthy controls (HC), were included in the analyses. We analyzed cerebrospinal fluid (CSF) levels of total tau protein (t‐tau), tau protein phosphorylated at threonine 231 (p‐ tau231), and factor score (FS) determined by combination of p‐ tau231and Mini‐ Mental State Examination (MMSE) in patients with AD and VaD, as well as in HC. We tested the diagnostic accuracy of these biomarkers in the CSF and FS (p‐tau231, MMSE) in differentiating AD from VaD and HC. Results: Total tau levels were significantly elevated in subjects with AD compared to HC, as well as in VaD subjects compared to HC. Discussion: p‐tau231 levels were significantly higher in patients with ADvsHC as well in patients with VaD vsHC. p‐ tau231 levels did not distinguish AD from VaD patients. Importantly, FS(p‐tau231 and MMSE) showed statistically significant differences in the distribution of subjects with AD and VaD. Conclusion: These results indicate that FS (p‐ tau231 and MMSE) has a strong potential to provide an early distinction between AD and VaD.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinika za psihijatriju Vrapče,
Opća bolnica Varaždin,
Klinički bolnički centar Zagreb
Profili:
Antonela Blažeković
(autor)
Fran Borovečki
(autor)
Danijela Kolenc
(autor)
Nataša Klepac
(autor)
Lea Langer Horvat
(autor)
Marina Boban
(autor)
Goran Šimić
(autor)
Zdenko Sonicki
(autor)
Ninoslav Mimica
(autor)
Mirjana Babić Leko
(autor)
Spomenka Kiđemet-Piskač
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE